AstraZeneca, Daiichi's Trodelvy rival fails to improve overall survival in breast cancer trial
AstraZeneca and Daiichi Sankyo’s TROP2-directed antibody-drug conjugate (ADC) has again failed to improve overall survival (OS) in a phase 3 trial. The latest miss happened in breast cancer, a setting in which Gilead’s rival Trodelvy significantly improved OS in a prior late-phase study.
AstraZeneca and Daiichi Sankyo report data from Phase III breast cancer trial
AstraZeneca and Daiichi Sankyo have reported results from the TROPION-Breast01 Phase III clinical trial of datopotamab deruxtecan (Dato-DXd) for breast cancer. The trial compared Dato-DXd to the investigator's choice of chemotherapy in patients with inoperable or metastatic hormone receptor (HR)-positive,
AstraZeneca's experimental drug disappoints in breast cancer survival trial
AstraZeneca said on Monday its experimental precision drug developed with Japan's Daiichi Sankyo did not significantly improve overall survival for patients with a type of breast cancer in a late-stage trial.
AstraZeneca drug fails to extend lives of breast cancer patients
A new AstraZeneca drug has failed to extend significantly the lives of breast cancer patients in a blow to the company’s ambitions to hit an $80bn revenue target by 2030. Datopotamab deruxtecan (Dato-DXd) is a new form of cancer treatment,
AstraZeneca Stock Dips On Surprise Miss For Gilead-Rivaling Cancer Drug
AstraZeneca stock slumped Monday after its Daiichi Sankyo-partnered drug missed its mark in a study of patients with breast cancer.
AstraZeneca's experimental cancer drug shows no significant improvement in overall survival
AstraZeneca said on Monday its experimental precision drug developed with Daiichi Sankyo did not significantly improve overall survival for patients with a type of breast cancer in a late-stage trial.
Daiichi Sankyo-Merck's 'guided-missile' cancer drug meets main goal in late-stage trial
Daiichi Sankyo and Merck said on Tuesday that their drug, patritumab deruxtecan, met the main goal of extending the time some ...
MM&M4d
Daiichi Sankyo launches first DTC ad for Enhertu, representing shift toward patient-centric oncology campaigns
Daiichi Sankyo has launched a new direct-to-consumer (DTC) campaign for Enhertu — the first DTC effort for its oncology unit ...
Pharmaceutical Technology17h
Daiichi Sankyo gets grant for monoclonal antibody for treating autoimmune diseases
Discover Daiichi Sankyo's groundbreaking patent for monoclonal antibodies targeting LAG-3, offering new hope for treating autoimmune diseases with enhanced efficacy.
FierceBiotech7d
Merck, Daiichi rack up phase 3 ADC lung cancer win but report 2 deaths, immature OS data
A phase 3 trial of Daiichi Sankyo and Merck & Co.’s HER3-directed antibody-drug conjugate (ADC) has hit its primary endpoint, ...
FiercePharma4d
Daiichi, AZ's first Enhertu DTC campaign kicks off during Thursday Night Football
As Enhertu’s reach continues to spread into additional forms of breast cancer, Daiichi Sankyo and AstraZeneca are ramping up ...
Yahoo Finance6d
Study: Merck and Daiichi's Lung Cancer Treatment Shows Promise
Merck MRK announced that a phase study evaluating its Daiichi Sankyo-partnered HER3-directed DXd antibody drug conjugate (ADC), patritumab deruxtecan, for treating EGFR-mutated non-small cell lung ...
PMLiVE4d
Daiichi Sankyo’s Vanflyta recommended by NICE for acute myeloid leukaemia
Daiichi Sankyo’s Vanflyta (quizartinib) has been recommended by the National Institute for Health and Care Excellence (NICE) ...
Daiichi Sankyo-Merck's cancer drug meets main goal in late-stage trial
Daiichi Sankyo and Merck said on Tuesday that their drug, patritumab deruxtecan, met the main goal in a late-stage study in ...
AstraZeneca, Daiichi’s Enhertu successor faces more questions after latest stumble
The partners said their antibody-drug conjugate datopotomab deruxtecan didn’t extend survival in a breast cancer study, ...
precisionmedicineonline1d
AstraZeneca, Daiichi Sankyo Hoping to Sway FDA of Dato-DXd Benefit Despite Overall Survival Miss
Despite showing a progression-free survival benefit, the antibody-drug conjugate did not improve overall survival in HR-positive, HER2-negative or -low breast cancer.